CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office...

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...

Development of the University of Queensland’s vaccine candidate remains CSL’s priority. However, we are currently in discussions with AstraZeneca and the Australian Government to assess...

Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma...

The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect. In...

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care. Less than a third of surveyed healthcare...

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia The first human trials using the University of Queensland’s (UQ) COVID-19...

Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic...

Plasma-derived therapeutic with potential to treat serious complications of COVID-19. MELBOURNE, AUSTRALIA – CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will...

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. Anthony Farina – Chief Communications Officer, CSL Limited 18 Mar 2020 As...